This inventor holds 1 USPTO granted patent. Top assignees: Carboexpert Inc., The Industry & Academic Cooperation in Chungnam National University (Iac). Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2025
Title: Jongtae Park: Innovator in Pharmaceutical Chemistry
Introduction
Jongtae Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of prodrugs for therapeutic applications. His innovative work focuses on enhancing drug solubility and stability, which is crucial for effective treatment.
Latest Patents
One of Jongtae Park's most recent patents is the "Inotodiol ester derivative precursor drug." This patent relates to an ester derivative prodrug of inotodiol and its use in treating various inflammatory and allergic diseases. The prodrug demonstrates increased solubility in both inorganic and organic solvents, along with improved stability, making it a promising candidate for therapeutic applications.
Career Highlights
Throughout his career, Jongtae Park has worked with several organizations, including Carboexpert Inc. and the Industry & Academic Cooperation in Chungnam National University. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to advancements in pharmaceutical research.
Collaborations
Jongtae Park has collaborated with notable colleagues, including Phu Cuong Nguyen and Kyubeen Park. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the industry.
Conclusion
Jongtae Park's contributions to pharmaceutical chemistry, particularly through his innovative prodrug development, highlight his role as a significant inventor in the field. His work not only advances scientific knowledge but also holds the potential for improving treatment options for patients with inflammatory and allergic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile